Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study.

Sci Rep · 2025 · PMC12219119 · PMID 40593014

Europe PMC DOI

hedged sentence

0.3400

closest p · 6.8× alpha

0.3400

boldest claim

The sentences

did not reach statistical significancep = 0.34not close (p > 0.1)

Here, our study fills the research gap in this area, demonstrating that osimertinib plus chemotherapy improved PFS by 5.3 months compared to the osimertinib monotherapy group, although it did not reach statistical significance (26.0 months vs. 20.7 months, p = 0.34).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.